Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CT
Purpose: Bone scintigraphy is the standard of reference in bone metastases in prostate cancer patients. However, new radiotracers employed in prostate-specific membrane antigen (PSMA)-ligands has led to the growing importance of PET/CT as diagnostic tool. The aim of our study was to investigate the...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-07-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/10/3/68 |
id |
doaj-044e79fa353041308a88ed4cb574e56a |
---|---|
record_format |
Article |
spelling |
doaj-044e79fa353041308a88ed4cb574e56a2020-11-25T03:53:22ZengMDPI AGPharmaceuticals1424-82472017-07-011036810.3390/ph10030068ph10030068Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CTLena Thomas0Caroline Balmus1Hojjat Ahmadzadehfar2Markus Essler3Holger Strunk4Ralph A. Bundschuh5Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Bonn, Bonn D-53127, GermanyKlinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Bonn, Bonn D-53127, GermanyKlinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Bonn, Bonn D-53127, GermanyKlinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Bonn, Bonn D-53127, GermanyRadiologische Klinik, Universitätsklinikum Bonn, Bonn D-53012, GermanyKlinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Bonn, Bonn D-53127, GermanyPurpose: Bone scintigraphy is the standard of reference in bone metastases in prostate cancer patients. However, new radiotracers employed in prostate-specific membrane antigen (PSMA)-ligands has led to the growing importance of PET/CT as diagnostic tool. The aim of our study was to investigate the difference between bone scan and PSMA-PET/CT for the detection of bone metastases in prostate cancer. Methods: Thirty patients with bone metastases originating from prostate cancer were examined by 99mTc-MDP bone scan and 68Ga-PSMA-PET/CT within an average of 21 days. Bone scans were analyzed visually according to the number of lesions and using the software package ExiniBONE by Exini Diagnostics. PET/CT data was analyzed visually. Numbers of detected lesions were compared for the different methods for the whole patient and for different regions. In addition, results were compared to serum prostate-specific antigen (PSA), alkaline phosphatase (ALP), bone alkaline phosphatase (bALP), pro gastrin releasing peptide (pGRP) and eastern cooperative oncology group (ECOG) performance status. Results: In the bone scans, visual and semiautomatic lesion detection showed similar results with an average of 19.4 and 17.8 detected bone lesion per patient. However, in PSMA-PET/CT, on average double the numbers of lesions (40.0) were detected. The largest differences were found in the thorax and pelvis, which can be explained by the advantages of tomographic imaging. Bland-Altman analysis showed greater differences in patients with large numbers of bone metastases. Conclusion: No significant difference was found when using semiautomatic analysis compared to visual reading for bone scans. Fewer bone metastases were detected in bone scans than in PSMA-PET/CT. However, in none of our patients would the difference have led to clinical consequences. Therefore, it seems that for patients undergoing PSMA-PET/CT, there is no need to perform additional bone scans if the appropriate PET/CT protocols are applied.https://www.mdpi.com/1424-8247/10/3/68prostate cancerbone scan indexbone scintigraphyPSMA-PET/CT |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lena Thomas Caroline Balmus Hojjat Ahmadzadehfar Markus Essler Holger Strunk Ralph A. Bundschuh |
spellingShingle |
Lena Thomas Caroline Balmus Hojjat Ahmadzadehfar Markus Essler Holger Strunk Ralph A. Bundschuh Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CT Pharmaceuticals prostate cancer bone scan index bone scintigraphy PSMA-PET/CT |
author_facet |
Lena Thomas Caroline Balmus Hojjat Ahmadzadehfar Markus Essler Holger Strunk Ralph A. Bundschuh |
author_sort |
Lena Thomas |
title |
Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CT |
title_short |
Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CT |
title_full |
Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CT |
title_fullStr |
Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CT |
title_full_unstemmed |
Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CT |
title_sort |
assessment of bone metastases in patients with prostate cancer—a comparison between 99mtc-bone-scintigraphy and [68ga]ga-psma pet/ct |
publisher |
MDPI AG |
series |
Pharmaceuticals |
issn |
1424-8247 |
publishDate |
2017-07-01 |
description |
Purpose: Bone scintigraphy is the standard of reference in bone metastases in prostate cancer patients. However, new radiotracers employed in prostate-specific membrane antigen (PSMA)-ligands has led to the growing importance of PET/CT as diagnostic tool. The aim of our study was to investigate the difference between bone scan and PSMA-PET/CT for the detection of bone metastases in prostate cancer. Methods: Thirty patients with bone metastases originating from prostate cancer were examined by 99mTc-MDP bone scan and 68Ga-PSMA-PET/CT within an average of 21 days. Bone scans were analyzed visually according to the number of lesions and using the software package ExiniBONE by Exini Diagnostics. PET/CT data was analyzed visually. Numbers of detected lesions were compared for the different methods for the whole patient and for different regions. In addition, results were compared to serum prostate-specific antigen (PSA), alkaline phosphatase (ALP), bone alkaline phosphatase (bALP), pro gastrin releasing peptide (pGRP) and eastern cooperative oncology group (ECOG) performance status. Results: In the bone scans, visual and semiautomatic lesion detection showed similar results with an average of 19.4 and 17.8 detected bone lesion per patient. However, in PSMA-PET/CT, on average double the numbers of lesions (40.0) were detected. The largest differences were found in the thorax and pelvis, which can be explained by the advantages of tomographic imaging. Bland-Altman analysis showed greater differences in patients with large numbers of bone metastases. Conclusion: No significant difference was found when using semiautomatic analysis compared to visual reading for bone scans. Fewer bone metastases were detected in bone scans than in PSMA-PET/CT. However, in none of our patients would the difference have led to clinical consequences. Therefore, it seems that for patients undergoing PSMA-PET/CT, there is no need to perform additional bone scans if the appropriate PET/CT protocols are applied. |
topic |
prostate cancer bone scan index bone scintigraphy PSMA-PET/CT |
url |
https://www.mdpi.com/1424-8247/10/3/68 |
work_keys_str_mv |
AT lenathomas assessmentofbonemetastasesinpatientswithprostatecanceracomparisonbetween99mtcbonescintigraphyand68gagapsmapetct AT carolinebalmus assessmentofbonemetastasesinpatientswithprostatecanceracomparisonbetween99mtcbonescintigraphyand68gagapsmapetct AT hojjatahmadzadehfar assessmentofbonemetastasesinpatientswithprostatecanceracomparisonbetween99mtcbonescintigraphyand68gagapsmapetct AT markusessler assessmentofbonemetastasesinpatientswithprostatecanceracomparisonbetween99mtcbonescintigraphyand68gagapsmapetct AT holgerstrunk assessmentofbonemetastasesinpatientswithprostatecanceracomparisonbetween99mtcbonescintigraphyand68gagapsmapetct AT ralphabundschuh assessmentofbonemetastasesinpatientswithprostatecanceracomparisonbetween99mtcbonescintigraphyand68gagapsmapetct |
_version_ |
1724478492200927232 |